Patents by Inventor Richard G. Jarman, III

Richard G. Jarman, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following ZIKV infection or vaccination
    Patent number: 11884718
    Abstract: The invention described herein provides antibodies to Zika virus. The novel polypeptides are useful alone or as portions of larger molecules, such as antibodies or antibody fragments, that can be used to treat or prevent infection of Zika virus.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: January 30, 2024
    Assignees: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Beth Israeli Deaconess Medical Center, Inc., The Government Of The United States As Represented By The Secretary Of The Army
    Inventors: Shelly Krebs, Gina Donofrio, Vincent Dussupt, Kayvon Modjarrad, Dan Barouch, Richard G. Jarman, III, Nelson L. Michael, Gordon Joyce, Rajeshwer Singh Sankhala, Kathryn Elaine Stephenson
  • INACTIVATED VACCINE FOR CHIKUNGUNYA VIRUS
    Publication number: 20220347286
    Abstract: The disclosure generally provides a purified inactivated chikungunya virus (CHIKV), methods for producing the purified inactivated CHIKV, immunogenic compositions and vaccines comprising the purified inactivated CHIKV and methods for the prevention and/or treatment of infection by CHIKV.
    Type: Application
    Filed: June 28, 2022
    Publication date: November 3, 2022
    Inventors: Stephen J. THOMAS, Kenneth H. ECKELS, Joseph R. PUTNAK, Richard G. JARMAN, III, Rafael Antonio DE LA BARRERA
  • Potent Zika Virus-Specific and Cross-Neutralizing Monoclonal Antibodies to Zika and Dengue Viruses Following Zikv Infection or Vaccination
    Publication number: 20210238262
    Abstract: The invention described herein provides antibodies to Zika virus. The novel polypeptides are useful alone or as portions of larger molecules, such as antibodies or antibody fragments, that can be used to treat or prevent infection of Zika virus.
    Type: Application
    Filed: April 24, 2019
    Publication date: August 5, 2021
    Applicants: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Beth Israel Deaconess Medical Center, Inc., The Government of the United States as Represented by the Secretary of the Army
    Inventors: Shelly Krebs, Gina Donofrio, Vincent Dussupt, Kayvon Modjarrad, Dan Barouch, Richard G. Jarman, III, Nelson L. Michael, Gordon Joyce